Veru Inc. (VERU)
- Previous Close
1.2750 - Open
1.3000 - Bid 1.2800 x 1600
- Ask 1.3700 x 500
- Day's Range
1.2800 - 1.3800 - 52 Week Range
0.3600 - 1.9200 - Volume
1,528,962 - Avg. Volume
2,422,414 - Market Cap (intraday)
193.223M - Beta (5Y Monthly) -0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7000 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 28, 2014
- 1y Target Est
2.75
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
verupharma.comRecent News: VERU
Performance Overview: VERU
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VERU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VERU
Valuation Measures
Market Cap
193.22M
Enterprise Value
166.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.46
Price/Book (mrq)
3.74
Enterprise Value/Revenue
10.47
Enterprise Value/EBITDA
-2.77
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.09%
Return on Equity (ttm)
-124.57%
Revenue (ttm)
15.93M
Net Income Avi to Common (ttm)
-62.72M
Diluted EPS (ttm)
-0.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
40.58M
Total Debt/Equity (mrq)
27.73%
Levered Free Cash Flow (ttm)
-39.93M